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Asthma controlAbstract To asthmatic patients with moderate to severe persistent asthma, two main treatment
options are recommended: The combination of a long-acting inhaled b2-agonist with inhaled
corticosteroids or the use of a higher dose of inhaled corticosteroids. The aim of this study was
to evaluate which drug option is more favorable.
Patients and methods: This study included 60 asthmatic patients uncontrolled on low doses of
ICSs. They were randomized into two groups. Group (1): 30 patients received twice daily inhaled
formetrol and budesonide in a dose of 12 mcg and 400 mcg, respectively. Group (2): 30 patients
received two fold the previous dose of budesonide 800 mcg/BID alone. A comparative study was
carried out at Outpatient Chest Clinic of Fayoum Hospital University for a period of 24 weeks
using the spirometric data of patients of the two groups before and after treatment.
Results: Results showed that the combination therapy of inhaled formetrol and budesonide is
modestly more effective in the reduction of symptoms and in improving the lung functions than
with a higher dose of budesonide alone.
Conclusion: Adding formetrol in a dose of 12 lg plus budesonide in a dose 400 lg b.i.d. is more
favorable in treatment of asthma than a higher dose of budesonide (800 lg b.i.d).
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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Asthma is a chronic inﬂammatory disorder of the airways in
which many cells and cellular elements play a role. The chronic
inﬂammation is associated with airway hyperresponsiveness
that leads to recurrent episodes of wheezing, breathlessness,
chest tightness and coughing, particularly at night or in early
morning. These episodes are usually associated with wide
spread, but variable, airﬂow obstruction within the lung that
is often reversible either spontaneously or with treatment [5].
A number of factors that inﬂuence a person’s risk of devel-
oping asthma have been identiﬁed. These can be divided into
host factors (primarily genetic) and environmental factors
[3]. Measurements of lung function (spirometry) provide an
assessment of the severity of airﬂow limitation, its reversibility,
and its variability provide conﬁrmation of the diagnosis of
asthma [1].
The aim of asthma treatment is to achieve and maintain
clinical control for prolonged periods [2].
Medications to treat asthma can be classiﬁed as controllers
or relievers. Controllers are medications taken daily on a
long-term basis to keep asthma under clinical control chieﬂy
through their ant-inﬂammatory effects.
Relievers are medications used on an as-needed basis that
act quickly to reverse bronchoconstriction and relieve its
symptoms [5].
To reach clinical control, add on therapy of inhaled LABA
to ICS is preferred over increasing the dose of inhaled
glucocorticosteroids. Long-acting inhaled b2-agonist, includ-
ing formetrol should not be used as monotherapy in asthma
as these medications do not appear to inﬂuence airway inﬂam-
mation in asthma. The addition of the long-acting inhaled
b2-agonist to the daily regimen of inhaled glucocorticosteroids
improves symptom scores, decreases nocturnal asthma symp-
toms, improves lung function, decreases the use of rapid-acting
inhaled b2-agonist [10] and achieves clinical control of asthma
in more patients, more rapidly, and at a lower dose of ICS than
ICS alone [2].
The study was conducted on asthmatic patients among
those attending the outpatient chest clinic in Fayoum Hospital
University during the period from January 2010 till December
2012.
The study included 60 patients with moderate to severe
persistent asthma, uncontrolled on low doses of ICSs (budesonide
or beclomethasone dry powder inhaler, 400 mcg/day).
All of these patients were >18 years old.
Exclusion criteria
Patients using systemic corticosteroids, those having respira-
tory infections affecting asthma control within the previous
4 weeks, patients with severe cardio-pulmonary disease or
other concomitant disease and smoking patients were excluded.
The patients included were randomized into two groups:
 Group 1: 30 patients received twice daily inhaled formetrol
and budesonide in the form of dry powder inhaler
(aerolizer) in a dose of 12 mcg and 400 mcg,
 Group 2: 30 patients received two fold the previous dose of
budesonide which is the maximum in the form of dry
powder inhaler (aerolizer) in a dose of 800 mcg/BID.Treatment with systemic anti-histaminic or other anti
asthma products will not be permitted.
These individuals were subjected to the following:
1. Full history taking with proper analysis of the complaint
and full history of atopic state.
2. Full clinical examination: general and local.
3. Chest X-ray.
4. Routine laboratory investigation.
5. Pulmonary function tests: The patients were instructed to
stop medications 24 h before performing the test to avoid
faulty results. The spirometric parameters estimated by
using the Compact Vitalograph were:
a. Forced vital capacity (FVC).
b. Forced expiratory volume in the ﬁrst second (FEV1).
c. FEV1/FVC ratio.
d. Peak expiratory ﬂow rate (PEFR). The test was repeated
3 times and the highest result was recorded.
6. Reversibility testing using repeated neubilization by 5 mg
salbutamol and 500 mcg of ipratropium.
Any patient <12% improvement in FEV1 was considered
COPD patient and excluded.
The patients were started on predetermined therapy for a
period of 6 months during which they were weekly supervised
in the out-patient Chest Clinic at Fayoum Hospital University.
At these visits, the patient’s questions were discussed, and
any problems with asthma and its treatment are reviewed.
Checking of the inhaler device technique with correction and
re-checking if it is inadequate were done until the period of
treatment ended.
At the end of the test pulmonary function tests (spirometry)
were repeated by comparing their results with those of the tests
previously done before the therapy.
Adherence to therapy was assessed by reviewing patient’s
questionnaire which was done at the clinic before initiating
the treatment and by the end of the predetermined period of
treatment.
At the end of the period of the study all the data were
collected, tabulated and statistically analyzed.
Statistical analysis
Statistical analysis for the obtained data was carried out to
determine the effect of adding inhaled formetrol to inhaled
budesonide compared to a higher dose of inhaled budesonide
in improving asthma control using descriptive analysis of the
results, Cross tabulation test, Student’s t-test, Fisher’s exact
test, and Paired samples t-test. Statistical package for social
science (SPSS) software version 17 was used.
Results
This study was conducted on asthmatic patients among those
attending the outpatient chest clinic in Fayoum Hospital
University. Their ages ranged from 20 to 60 years (with
moderate to severe asthma).
Table 1 shows comparison between mean (SD) of FVC,
FEV1, FEV1 ratio, and PEFR before and after therapy of
the two groups shows that; mean (SD) of FVC of group 1
Figure 1 FVC of both groups.
Figure 2 FEV1 of both groups.
Figure 3 FEV1/FVC ratio of both groups.
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respectively, with p-value equal to 0.662 which indicates no
signiﬁcant difference in FVC before treatment, and mean
(SD) of FVC after treatment of group1& group 2 is 80.0
(2.3) and 75.6 (4.2), respectively, with p-value equal to 0.001
which indicates highly signiﬁcant differences in FVC after
treatment as shown in Fig. 1, mean (SD) of FEV1 of group
1 & group 2 before treatment is 55.8 (3.1) and 58.4 (6.8),
respectively, with p-value equal to 0.062 which indicates no
signiﬁcant difference in FEV1 before treatment, mean (SD)
of FEV1 of group 1 and group 2 after treatment is 65.7 (4.8)
and 62.0 (4.5), respectively, with p-value equal to 0.003 which
indicates highly signiﬁcant differences in FEV1 after treatment
as shown in Fig. 2, mean (SD) of FEV1/FVC ratio of group 1
and group 2 before treatment is 65.7 (3.1) and 67.6 (5.9)
respectively with p-value equal to 0.110 which indicates no
signiﬁcant difference in FEV1 ratio before treatment, and
mean (SD) of FEV1 ratio after treatment is 72.4 (4.5), and
68.7 (5.8), respectively with p-value equal to 0.005 which
indicates highly signiﬁcant differences in FEV1 ratio after
treatment as shown in Fig. 3, mean (SD) of PEFR before treat-
ment of group 1 & group 2 is 53.2 (5.5), and 50.1 (6.8), respec-
tively, with p-value equal 0.060 which indicates no signiﬁcant
difference in PEFR between both groups before treatment,
and mean of PEFR after treatment of group 1 and group 2
is 57.5 ± 5.6 and 54.4 ± 6.5, respectively, with p-value equal
to 0.045 which indicates signiﬁcant differences between both
groups in PEFR after treatment as shown in Fig. 4.
Discussion
The aim of our study was to compare the effect of adding
(LABA) formetrol to (ICS) budesonide versus increasing the
dose of budesonide alone in improving asthma control.
Descriptive statistical analysis shows a signiﬁcantly greater
improvement in lung function that was achieved by patients
treated with formetrol/budesonide regimen than among those
who received higher-dose budesonide regimen.
A 2011 Cochrane reviews examine the effect of adding a
LABA to ICS in various scenarios in adults with asthma.
The addition of LABA to ICS as ﬁrst line treatment in patients
who had persistent asthma and were steroid-naı¨ve compared
to ICS alone resulted in improvements in FEV1, symptoms
and reduced rescue beta2-agonist use compared to ICS in
our study with similar rates of adverse events while continuing
the same dose of ICS [4].Table 1 Comparison between group 1 and group 2 at before and after treatment according to FVC, FEV1, FEV1/FVC and PEFR.
TTT Group 1 Mean ± SD Group 2 Mean ± SD p-Value Sig.
FVC Before 72.6 ± 3.6 73.1 ± 5.1 0.662 NS
After 80.0 ± 2.3 75.6 ± 4.2 0.001 HS
FEV1 Before 55.8 ± 3.1 58.4 ± 6.8 0.062 NS
After 65.7 ± 4.8 62.0 ± 4.5 0.003 HS
FEV1/FVC Before 65.7 ± 3.1 67.6 ± 5.9 0.110 NS
After 68.7 ± 5.3 72.4 ± 4.5 0.005 HS
PEFR Before 50.1 ± 6.8 53.2 ± 5.5 0.060 NS
After 54.4 ± 6.5 57.5 ± 5.6 0.045 S
Figure 4 PEFR of both groups.
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results to those of our study. They observed that patients
who received budesonide/formetrol as maintenance and relie-
ver showing signiﬁcant improvement in lung functions in terms
of both PEFR and FEV1 p< 0.001. Patients who required
fewer as-needed inhalations each day (treatment difference:
0.34), had more symptom-free days p= 0.0043 and more
asthma control days p= 0.0012 than those on a higher dose
of budesonide. The STEAM study was a 6-month, random-
ized, double blind, parallel-group study done in patients with
mild to-moderate asthma (mean baseline forced expiratory
volume over 1 min [FEV1] 75% expected) [8].
The STEP study by Scicchitano et al. [9] compared the
budesonide/formetrol maintenance and reliever regimen with
a higher-dose budesonide regimen in patients with moderate
to severe asthma (mean baseline FEV1 70% predicted). It
was a 12 month study and recruited 1890 patients the majority
of whom (83%) were classed as having severe asthma and
showed similar results to those of our study. A signiﬁcantly
greater improvement in lung function was achieved by patients
treated with formetrol/budesonide regimen than among those
who received a higher-dose budesonide regimen (FEV1 mean
treatment difference 0.101, p< 0.001) and also resulted in
more symptom-free and asthma control days p< 0.001.
Moreover, 45% fewer severe exacerbations per patient
required medical intervention with the budesonide/formetrol
regimen (p< 0.001) versus higher-dose budesonide [9].
Greening and colleagues who carried out the ﬁrst double-
blind study of 6-month duration in 426 patients with uncon-
trolled asthma [6] despite a low dose ICS (200 lg b.i.d.) found
little improvement in symptoms and morning peak expiratory
ﬂow rate (PEF) when the dose is increased to 500 lg b.i.d. but
much greater improvements were observed if salmetrol (50 lg
b.i.d.) was added to the same dose of beclomethasone. These
ﬁndings were conﬁrmed in the Landmark FACET study. This
study showed in 852 patients with moderately severe asthma
that the addition of formetrol (12 lg b.i.d.) to budesonide
(100 lg b.i.d.) more effectively controls symptoms and lung
functions than a fourfold increase in the dose of budesonide
(i.e. 400 lg b.i.d.), as shown in our study and this beneﬁt
persisted during the 12 months of study [7]. Moreover the
addition of formetrol (12 lg b.i.d.) signiﬁcantly reduced the
number of mild and severe attacks when added to both a
low (100 lg b.i.d.) and a high (400 lg b.i.d.) dose of
budesonide.
Conclusion
In conclusion, there is a modest advantage in adding long-act-
ing b2 agonist to inhaled corticosteroids, compared withincreasing the dose of inhaled corticosteroids in the reduction
of symptoms as well as improvement in lung function tests in
patients with sub-optimal control on low dose ICS
monotherapy.
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